Artivion to Participate in Upcoming Investor Conferences
Artivion (NYSE:AORT), a cardiac and vascular surgery company, announced its participation in two upcoming investor conferences. The company will present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 10:30 a.m. ET, with a live webcast available on their website. Additionally, management will participate in investor meetings at the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 12, 2025, though no webcast will be available for this event.
Artivion (NYSE:AORT), azienda specializzata in chirurgia cardiaca e vascolare, ha annunciato la sua partecipazione a due prossimi convegni per investitori. La società presenterà al Canaccord Genuity 45th Annual Growth Conference il 13 agosto 2025 alle 10:30 ET, con una diretta web disponibile sul loro sito. Inoltre, il management parteciperà a incontri con investitori al 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference il 12 agosto 2025, anche se per questo evento non sarà disponibile alcuna diretta web.
Artivion (NYSE:AORT), una empresa de cirugía cardíaca y vascular, anunció su participación en dos próximas conferencias para inversores. La compañía presentará en la Canaccord Genuity 45th Annual Growth Conference el 13 de agosto de 2025 a las 10:30 a.m. ET, con una transmisión en vivo disponible en su sitio web. Además, la dirección participará en reuniones con inversores en la 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference el 12 de agosto de 2025, aunque no habrá transmisión en vivo para este evento.
Artivion (NYSE:AORT)는 심장 및 혈관 수술 회사로, 다가오는 두 개의 투자자 컨퍼런스에 참여할 예정임을 발표했습니다. 회사는 2025년 8월 13일 오전 10시 30분(동부시간)에 Canaccord Genuity 45th Annual Growth Conference에서 발표하며, 웹사이트에서 생중계가 제공됩니다. 또한 경영진은 2025년 8월 12일에 열리는 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference에서 투자자 미팅에 참여할 예정이나, 이 행사에는 생중계가 제공되지 않습니다.
Artivion (NYSE:AORT), une entreprise spécialisée en chirurgie cardiaque et vasculaire, a annoncé sa participation à deux prochaines conférences pour investisseurs. La société présentera lors de la Canaccord Genuity 45th Annual Growth Conference le 13 août 2025 à 10h30 ET, avec une diffusion en direct disponible sur leur site web. De plus, la direction participera à des réunions avec des investisseurs lors de la 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference le 12 août 2025, bien qu’aucune diffusion en direct ne soit prévue pour cet événement.
Artivion (NYSE:AORT), ein Unternehmen für Herz- und Gefäßchirurgie, gab seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt. Das Unternehmen wird am Canaccord Genuity 45th Annual Growth Conference am 13. August 2025 um 10:30 Uhr ET präsentieren, mit einem Live-Webcast auf ihrer Website. Zudem wird das Management an Investorenmeetings auf der 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference am 12. August 2025 teilnehmen, jedoch wird es für diese Veranstaltung keinen Webcast geben.
- None.
- None.
Artivion's management team will present at the upcoming Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at the InterContinental Boston Hotel. The Company's presentation is scheduled to begin at 10:30 a.m. ET. A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.
Artivion management will also be participating in investor meetings at the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 12, 2025. Due to the format of this event no webcast will be available.
About Artivion, Inc.
Headquartered in suburban
Contact:
Artivion | Gilmartin Group LLC |
Lance A. Berry | Brian Johnston / Laine Morgan |
Executive Vice President & | Phone: 332-895-3222 |
Chief Financial Officer | |
Phone: 770-419-3355 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-to-participate-in-upcoming-investor-conferences-302517744.html
SOURCE Artivion, Inc.